肿瘤细胞治疗研究
FRONTIER PAPERS
Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors
肿瘤学的治疗范式正在经历由抗体药物偶联物（ADC）和双特异性抗体（bsAb）驱动的深刻变革。
Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response.
72 名参与者的一个亚组接受了 CARTx 后疫苗反应的评估。
Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target
基于特异性、疗效和靶抗原丢失，CARLY3 代表了一种针对非霍奇金淋巴瘤的潜在新型 CAR 治疗。
ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma.
CD19 CAR-T 疗法在复发/难治性非霍奇金淋巴瘤（NHL）中已取得显著缓解。
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting.
在过去几年中，双靶点嵌合抗原受体（CAR）T细胞疗法已被用于血液系统恶性肿瘤的治疗，以减少治疗失败，特别是在抗原逃逸的情况下。
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study.
这些数据支持在CAR-T细胞治疗前后考虑接种流感疫苗及其他相关病原体（如SARS-CoV-2）疫苗，无论是否存在低丙种球蛋白血症或B细胞发育不全。
Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis.
我们为 IPDMA 确定了 89 项试验，共纳入 2,331 例患者。
Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A C
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在嵌合抗原受体（CAR）T细胞治疗（CAR-T）接受者中的死亡率接近40%。
Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.
近年来，结直肠癌（CRC）和乳腺癌（BC）的发病率在全球范围内上升，并因缺乏选择性抗肿瘤疗法而导致更高的死亡率。
B cell deficiency promotes the initiation and progression of lung cancer.
目前商业化的靶向 CD19 和 BCMA 的 CAR-T 细胞疗法在治疗 B 细胞恶性肿瘤方面显示出巨大疗效。
MEMBER ACCOUNT
登录成功会直接打开下一页。
